Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "RTS"

1807 News Found

Aster DM Healthcare to invest Rs. 850 crore in next 3 years in Kerala
News | February 22, 2025

Aster DM Healthcare to invest Rs. 850 crore in next 3 years in Kerala

Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects


IMCD showcases ‘Skinification’ trend at HPCI India 2025
News | February 19, 2025

IMCD showcases ‘Skinification’ trend at HPCI India 2025

IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care


Lupin receives “A-” leadership rating from CDP in climate change and water security
Sustainability | February 19, 2025

Lupin receives “A-” leadership rating from CDP in climate change and water security

This rating reflects Lupin's leadership in environmental transparency and performance


Dr. Prabhavathi. R joins HEJJE
People | February 18, 2025

Dr. Prabhavathi. R joins HEJJE

Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders


ALPLA opens new manufacturing plant in Thailand
Packaging | February 17, 2025

ALPLA opens new manufacturing plant in Thailand

ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies


Bayer files for approval of finerenone in heart failure in Japan
News | February 15, 2025

Bayer files for approval of finerenone in heart failure in Japan

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure


FDA approves EMBLAVEO for the treatment of adults with complicated intra-abdominal infections
News | February 08, 2025

FDA approves EMBLAVEO for the treatment of adults with complicated intra-abdominal infections

EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA


Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis
Diagnostic Center | February 07, 2025

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis

Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo